Actively Recruiting

Age: 18Years +
FEMALE
NCT03877796

Clinical Pre-screening Protocol for Ovarian Cancer

Led by Allarity Therapeutics · Updated on 2025-10-30

60

Participants Needed

5

Research Sites

398 weeks

Total Duration

On this page

Sponsors

A

Allarity Therapeutics

Lead Sponsor

A

Amarex Clinical Research

Collaborating Sponsor

AI-Summary

What this Trial Is About

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

CONDITIONS

Official Title

Clinical Pre-screening Protocol for Ovarian Cancer

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with histological confirmed epithelia ovarian cancer
  • Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible
  • Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
  • FFPE tumor tissue available
Not Eligible

You will not qualify if you...

  • Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy
  • Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Completed

2

OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, United States, 73104

Actively Recruiting

3

Swedish Center for Research and Innovation

Seattle, Washington, United States, 98122

Actively Recruiting

4

Beatson West of Scotland Cancer Centre

Glasgow, Scotland, United Kingdom, G12 0YN

Active, Not Recruiting

5

Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital

London, United Kingdom

Active, Not Recruiting

Loading map...

Research Team

U

US: Kathleen Moore

CONTACT

E

Europe: Rebecca Kristeleit

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Clinical Pre-screening Protocol for Ovarian Cancer | DecenTrialz